<DOC>
	<DOCNO>NCT00305149</DOCNO>
	<brief_summary>.This study try address change chemotherapy dosage accord individual patient response initial cycle chemotherapy order reduce cumulative dose chemotherapy.The study include patient early unfavorable advanced hodgkin lymphoma . Patients low risk start standard beacopp high risk patient start escalated beacopp.Following 2 cycle therapy patient reassessed.Based scintigraphy result decision make regard therapylative chemotherapy early responder maximize dose intensity late responder .</brief_summary>
	<brief_title>Risk Adapted Beacopp Regimen Standard High Risk Hodgkin Lymphoma</brief_title>
	<detailed_description>Patients eligible early unfavorable disease patient present stage III IV disease .Pt assign receive 6 cycle Bleomycin Etoposide , Doxorubicin , Cyclophosphamide Procarbazine , Prednisone ( BEACOPP ) increase dose BEACOPP . ( IDB ) . Patient Stage I II ³4 site disease , age ³50 , ESR³50 “ B ” symptom lymphocyte deplete histology “ E ” site , bulky disease define early unfavorable disease give standard BEACOPP ( SB ) . Those I , II B bulky disease Stage III , IV define accord IPS . Increased dose BEACOPP ( IDB ) cycle therapy initiated patient IPS 3 risk factor ( high risk ) Standard BEACOPP ( SB ) cycle initiate score 0-2 ( standard risk ) . All patient baseline GA67 hybrid PET\CT scan diagnosis post first cycle gallium scan second cycle hybrid PET\CT . Upon scan result therapy plan give addition 4 cycle . Those negative scan receive cycle SB third cycle . Dose reduce level I III patient hospitalize due fever neutropenia 5 day longer pt episode sepsis unstable vital sign . Patient residual uptake interpret positive scan additional cycle IDB total 6 cycle</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>stage IIIA/B adverse prognostic IIIIV disease Age 18 Over Performance status ECOG 03 Hematopoietic WBC least 4000/mm3 ( unless document bone marrow involvement ) Hepatic bilirubin great 5 mg/dL RENAL : Creatinine great 2.0mg/dL pregnant nursing Fertile patient must use effective contraception HIV negative No malignancy within past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>BEACOPP</keyword>
	<keyword>PET</keyword>
	<keyword>Gallium</keyword>
	<keyword>Tailored therapy</keyword>
</DOC>